SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Amortization of Debt Discount (Premium)
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Amortization of Debt Discount (Premium) of $12.12 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2026-03-31 was $12.12K, a 85.49% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2025-12-31 was $13.92K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt discount (premium) for the quarter ending 2025-09-30 was $18.18K, a 92.65% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt discount (premium) for fiscal 2025 was $62.03K, a 94.25% decline from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt discount (premium) for fiscal 2024 was $1.08M, a 49.16% decline from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt discount (premium) for fiscal 2023 was $2.12M, a 462.57% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. amortization of debt discount (premium) for fiscal 2022 was $377.38K, a 11035.56% increase from fiscal 2021.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $12.12K 10-Q · filed 2026-09-24 | $26.04K derived: sum of 3 quarters · filed 2026-09-24 | $44.23K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2026-03-31 | $12.12K 10-Q · filed 2026-05-15 | $26.04K derived: sum of 2 quarters · filed 2026-05-15 | $44.23K derived: sum of 3 quarters · filed 2026-05-15 | $67.62K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-12-31 | $13.92K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $32.10K derived: sum of 2 quarters · filed 2026-03-31 | $55.49K derived: sum of 3 quarters · filed 2026-09-24 | $62.03K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $18.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $41.57K derived: sum of 2 quarters · filed 2026-09-24 | $48.11K 10-Q · filed 2025-11-13 | $48.11K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-06-30 | $23.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $29.93K 10-Q · filed 2026-09-24 | $29.93K derived: sum of 3 quarters · filed 2026-09-24 | $277.36K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-03-31 | $6.54K 10-Q · filed 2026-05-15 | $6.54K derived: sum of 2 quarters · filed 2026-05-15 | $253.97K derived: sum of 3 quarters · filed 2026-05-15 | $640.47K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $247.43K derived: sum of 2 quarters · filed 2026-03-31 | $633.93K derived: sum of 3 quarters · filed 2026-03-31 | $1.08M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $247.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $633.93K derived: sum of 2 quarters · filed 2025-11-13 | $1.08M 10-Q · filed 2025-11-13 | $1.55M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $386.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $832.01K 10-Q · filed 2025-08-13 | $1.30M derived: sum of 3 quarters · filed 2025-08-13 | $1.84M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $445.51K 10-Q · filed 2025-05-08 | $913.83K derived: sum of 2 quarters · filed 2025-05-08 | $1.45M derived: sum of 3 quarters · filed 2025-05-08 | $2.00M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $468.32K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.01M derived: sum of 2 quarters · filed 2025-02-26 | $1.56M derived: sum of 3 quarters · filed 2025-02-26 | $2.12M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $538.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.09M derived: sum of 2 quarters · filed 2024-11-13 | $1.65M 10-Q · filed 2024-11-13 | $1.15M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $549.13K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | $1.12M 10-Q · filed 2024-09-04 | $608.30K derived: sum of 3 quarters · filed 2024-09-04 | $1.22M derived: sum of 4 quarters · filed 2024-09-04 | |
| 2023-03-31 | $567.30K 10-Q/A · filed 2024-09-04 | $59.18K derived: sum of 2 quarters · filed 2024-09-04 | $666.15K derived: sum of 3 quarters · filed 2024-09-04 | $815.11K derived: sum of 4 quarters · filed 2024-09-04 | |
| 2022-12-31 | -$508.12K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $98.85K derived: sum of 2 quarters · filed 2024-09-04 | $247.82K derived: sum of 3 quarters · filed 2024-09-04 | $377.38K 10-K/A · filed 2024-09-04 | $885.50K 10-K · filed 2023-03-15 |
| 2022-09-30 | $606.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $755.94K derived: sum of 2 quarters · filed 2023-11-13 | $885.50K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $148.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $278.53K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $129.57K 10-Q · filed 2023-05-25 | ||||
| 2021-12-31 | $3.39K 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |